Follow-up of patients with refractory or relapsed multiple myeloma after allogeneic hematopoietic cell transplantation.

The incorporation of proteasome inhibitors and immunomodulatory drugs into transplant protocols has the potential to improve outcomes and refine the role of allogeneic HCT for the treatment of multiple myeloma as a platform for long-term disease control.